Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

Inclusion Criteria:

• Male or female ≥18 and ≤80 years of age at time of screening

• Diagnosed with rheumatoid arthritis as determined by meeting 1987 American College ofRheumatology (ACR) classification criteria and has had rheumatoid arthritis for atleast 6 months

• Moderate rheumatoid arthritis during screening, as defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) > 3.2 and ≤ 5.1

• Active rheumatoid arthritis defined as ≥ 3 swollen joints (out of 28 joints examined)and ≥ 3 tender/painful joints (out of 28 joints examined) at screening and baseline. (A full 66/68 count joint count will be performed at baseline, but only joints in the 28-count joint count will be considered for eligibility. The 28-joint count consistsof the finger joints excluding the distal interphalangeal joints, the wrists, elbows,shoulders, and knees)

• Must be currently taking a DMARD such as methotrexate, sulfasalazine, leflunomide,minocycline, and/or hydroxychloroquine

Exclusion Criteria:

• Prosthetic joint infection within 5 years of screening or native joint infectionwithin 1 year of screening

• Class IV rheumatoid arthritis according to ACR revised response criteria

• Any active infection (including chronic or localized infections) for whichanti-infectives were indicated within 28 days prior to first investigational productdose

• Previously used more than one experimental biologic DMARD. Patient with prior use ofno more than one experimental biologic is permitted if the subject received no morethan 8 weeks of treatment. The use of the experimental biologic must not have occurredwithin 2 months of the first dose of investigational product

• Previously used more than one commercially available biologic DMARD. Subject withprior use of no more than one commercially available biologic is permitted if thepatient received no more than 8 weeks of treatment and did not discontinue because oflack of effect. The use of the biologic must not have occurred within 2 months of thefirst dose of investigational product. Acceptable prior use of biologics include thefollowing examples:

• No more than 4 injections of adalimumab

• No more than 8 (50 mg) injections of etanercept

• No more than 2 infusions of infliximab

• No more than 2 infusions of abatacept

• Additional inclusion (exclusion) criteria may apply